The Chi Square analysis between mutational score reflecting the presence of at least one mutation in any of the seven most frequently cancer-specific mutated genes identified in our panel (TP53, FAT1, FGF3, FLG, CDKN2A, KMT2C, and NSD1) and clinicopathological variables available in the TCGA data set for HNSCC showed that the mutation score was significantly associated negatively with differentiation (p<0.001), and positively with perineural invasion (p=0.010), and clinical T-stage (p<0.001). This evidence concerns the gene TP53 and cancer.